Lexaria Bioscience Corp. (LEXX) has a negative trailing P/E of -1.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -51.67%, forward earnings yield 131.58%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.4 | 0.14 | 24.61 | 160.78 | - |
| 2017 | -4.7 | -0.32 | 2.92 | 137.90 | - |
| 2018 | -1.6 | -0.01 | 4.44 | 24.46 | - |
| 2019 | -2.8 | 0.07 | 4.87 | 52.18 | - |
| 2020 | -3.2 | 0.26 | 4.92 | 39.47 | - |
| 2021 | -6.8 | 0.19 | 2.06 | 37.79 | - |
| 2022 | -2.4 | -0.07 | 2.19 | 68.21 | - |
| 2023 | -1.0 | 0.06 | 2.28 | 30.70 | - |
| 2024 | -8.4 | 0.16 | 6.03 | 104.29 | - |
| 2025 | -1.3 | -0.03 | 5.30 | 22.44 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.83 | $40.72K | $-1.21M | -2983.4% |
| 2017 | $-0.95 | $63.64K | $-1.87M | -2937.3% |
| 2018 | $-2.79 | $433.29K | $-6.6M | -1523% |
| 2019 | $-1.62 | $222.61K | $-4.2M | -1885.8% |
| 2020 | $-1.45 | $384.54K | $-4.03M | -1048.1% |
| 2021 | $-0.57 | $722.74K | $-2.5M | -346.5% |
| 2022 | $-1.24 | $255.4K | $-7.27M | -2846.3% |
| 2023 | $-1.01 | $226.21K | $-6.66M | -2946.4% |
| 2024 | $-0.47 | $464.28K | $-5.8M | -1248.2% |
| 2025 | $-0.66 | $705.92K | $-11.9M | -1686% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.36 | $-0.46 – $-0.26 | $200K | $180.71K – $219.29K | 1 |
| 2027 | $-0.31 | $-0.35 – $-0.27 | $1.4M | $1.27M – $1.54M | 1 |
| 2028 | $-0.28 | $-0.32 – $-0.24 | $1.59M | $1.43M – $1.74M | 1 |
| 2029 | $1.34 | $1.17 – $1.51 | $70.19M | $63.42M – $76.95M | 1 |
